American Association for Cancer Research
10780432ccr192670-sup-227284_2_supp_5999068_q3jr1r.docx (181 kB)

Supplementary figures 1a-1c from Circulating Tumor Cells and Early Relapse in Node-positive Melanoma

Download (181 kB)
journal contribution
posted on 2023-03-31, 22:21 authored by Anthony Lucci, Carolyn S. Hall, Sapna P. Patel, Boomadevi Narendran, Jessica B. Bauldry, Richard E. Royal, Mandar Karhade, Joshua R. Upshaw, Jennifer A. Wargo, Isabella C. Glitza, Michael K.K. Wong, Rodabe N. Amaria, Hussein A. Tawbi, Adi Diab, Michael A. Davies, Jeffrey E. Gershenwald, Jeffrey E. Lee, Patrick Hwu, Merrick I. Ross

Box and Whisker Plots



There is a need for sensitive, reproducible biomarkers for patients with stage III melanoma to guide clinical decision making. Circulating tumor cells (CTCs) can be detected in patients with melanoma; however, there are limited data regarding their significance in stage III disease. The aim of this study was to determine whether CTCs are associated with early relapse in stage III melanoma. We prospectively assessed CTCs at first presentation in clinic (baseline) for 243 patients with stage III melanoma. CTCs were measured using the CellSearch System. Relapse-free survival (RFS) was compared between patients with one or more baseline CTC versus those with no CTCs. Log-rank test and Cox regression analysis were applied to establish associations of CTCs with RFS. At least one baseline CTC was identified in 90 of 243 (37%) patients. Forty-five (19%), 67 (28%), 118 (49%), and 13 (5%) patients were stage IIIA, IIIB, IIIC, or IIID, respectively. CTC detection was not associated with substage, or primary tumor characteristics. Multivariable analysis demonstrated that the detection of ≥1 baseline CTC was significantly associated with decreased 6-month RFS [log-rank, P < 0.0001; HR, 3.62, 95% confidence interval (CI), 1.78–7.36; P < 0.0001] and 54-month RFS (log-rank, P = 0.01; HR, 1.69; 95% CI, 1.13–2.54; P = 0.01). ≥1 CTC was independently associated with melanoma relapse, suggesting that CTC assessment may be useful to identify patients at risk for relapse who could derive benefit from adjuvant therapy.

Usage metrics

    Clinical Cancer Research



    Ref. manager